Director Guerrero Ramiro bought 37,595 MAIA Biotechnology shares at $1.32 per share on 2026-09-10, increasing his resulting holding to 773,296 shares. The purchase represents about 4.9% of that holding and is classified as an open-market purchase, giving investors a precise view of the transaction’s size within his reported position.
Key Highlights
- Transaction code P classifies Guerrero Ramiro’s purchase as an open-market transaction.
- Guerrero Ramiro’s reported holding after the purchase was 773,296 shares.
- The transaction represented about 4.9% of his resulting shareholding.
MAIA Biotechnology, Inc. (AMEX: MAIA) director Guerrero Ramiro bought 37,595 shares at $1.32 per share on 10 September 2026.
Purchase Classified as Open-Market Transaction
The transaction carries code P, which identifies an open-market purchase in the Form 4 transaction classification. The reported post-transaction position was 773,296 shares. The purchase price applies to each share acquired. The transaction record ties the $1.32 price specifically to the 37,595 shares bought by Ramiro. The transaction represented about 4.9% of Ramiro’s resulting shareholding.
FAQs
Q: How many MAIA Biotechnology shares did Guerrero Ramiro buy?
A: According to the filing, Guerrero Ramiro bought 37,595 MAIA Biotechnology shares at $1.32 per share. The purchase was reported on 10 September 2026 under SEC transaction code P.
Q: What was the impact of the MAIA Biotechnology director purchase?
A: Following the purchase, the filing reported that Guerrero Ramiro owned 773,296 MAIA Biotechnology shares. It also stated that the transaction represented about 4.9% of his resulting shareholding.
Q: Was Guerrero Ramiro’s MAIA Biotechnology transaction an open-market purchase?
A: Yes. SEC transaction code P identifies Guerrero Ramiro’s acquisition as an open-market purchase in the Form 4 filing. The reported transaction occurred on 10 September 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.